ClinicalTrials.gg
CompletedNCT00271258ADOKOTUpdated Jan 11, 2011

Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents

A Phase 3 interventional study of SODIUM DIVALPROATE in Bipolar Disorder, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2011-01-11.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Valproic Acid in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Valproic Acid · Bipolar Disorder.

Enrollment
9th of 41
200 · median 58
Started
2005
with 4 others
Phase 3
11 of 41
none open now
Registered
24th of 41
by date
Lead sponsor
3 of 41
Sanofi

Among the 41 studies testing Valproic Acid in Bipolar Disorder, this one is the 9th largest by enrollment, is one of 5 that started in 2005, is one of 11 in phase 3, and was the 24th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 41 studies testing Valproic Acid in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing Valproic Acid in Bipolar Disorder as a file.
02

Study summary

  • Main objective: To evaluate the clinical and physiological tolerance of sodium divalproate in manic, mixed or hypomanic episodes of bipolar disorder in adolescents treated for 6 months.
  • Secondary objective: To evaluate the efficacy of sodium divalproate in improving manic, mixed or hypomanic symptoms.
03

Conditions studied

  • Bipolar Disorder

Browse trials for

04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Adolescent boys or girls aged 13 to 18 inclusive
  • Weighing more than 40 kg
  • Capable of understanding the protocol
  • Who have given their written consent, as have their parents or legal guardian unless the adolescent has passed his/her 18th birthday
  • Presenting the diagnostic characteristics of manic, mixed or hypomanic episodes of bipolar disorder established in accordance with the DSM IV, gathered in a semi-structured interview (Mini International Neuropsychiatric Interview - M.I.N.I.)
  • With a score on the YMRS scale (Young Mania Rating Scale) >= 14 for the manic or mixed episode or >= 10 for the hypomanic episode
  • Absence in blood of valproic acid at the inclusion visit
  • Willing to use effective in the case of girls of . In this case the investigator should satisfy him/herself as to the psychological capacity of the patient to understand and undertake use of this contraception.
  • Whose physiological test results are normal: hepatic function, blood count, lipid levels, fasting blood glucose level, blood urea, blood ammonia, blood protein, serum creatinine levels and plasma ions

Exclusion Criteria:

  • General criteria:

    • Pregnant girls, or those breast-feeding or those for whom a pregnancy test is positive (blood beta HCG test)
    • Simultaneous participation in another study or in the 2 months preceding selection of the patient
  • Psychiatric criteria:

    • Established or known mental retardation
    • Autistic disorders
    • Established schizophrenia
    • Schizoaffective disorders
  • Somatic criteria:

    • Medical or organic disease of the CNS (epilepsy, tumour etc.)
    • Any known renal, cardiac or haematological disease, or disease of the immune system
    • Endocrine disorders and/or any biochemical abnormality known or existing at the moment of inclusion
  • Exclusion criteria linked to the treatment

    • Known to valproate or to sodium divalproate or to one of the constituents of the drug
    • Hepatic disease: acute hepatitis, chronic hepatitis, past personal or family history of severe hepatitis particularly caused by medicinal products, hepatic porphyria
    • Treatment with lamotrigine, (Lamictal)
    • Treatment with mefloquine, (Lariam)
    • Any treatment based on valproate
    • Treatment with methylphenidate (Ritalin)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants

Interventions

06

What researchers measure

Primary outcomes

  1. clinical examination

07

Study locations

1 site
  • Sanofi-Aventis
    Paris, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2005
First posted
Dec 30, 2005
Start
Jan 2005
CompletionActual
Jan 2007
Last update
Jan 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00271258
Lead sponsor
Sanofi
First posted
Dec 30, 2005
Start date
Jan 2005
Completion
Jan 2007
Last update
Jan 11, 2011

Study contacts

Marie SEBILLE, Dr
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion